39th week of 2017 patent applcation highlights part 8 |
Patent application number | Title | Published |
20170273934 | Treatment of Triple Receptor Negative Breast Cancer - The present invention relates to the use of a liposomal preparation for the manufacture of a pharmaceutical composition and the use of such a composition for the treatment of “triple receptor negative” breast cancer. | 2017-09-28 |
20170273935 | CINEOLE-CONTAINING COMPOSITION FOR NASAL APPLICATION - The invention relates to a pharmaceutical composition containing cineole for topical, in particular nasal, preferably intranasal application, to the use thereof and to an application device containing said pharmaceutical composition. | 2017-09-28 |
20170273936 | USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR USE IN THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATION OR OF MORTALITY - Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto. | 2017-09-28 |
20170273937 | ENKEPHALIN-INFLUENCING COMPOSITION AND METHOD - A composition which includes Phenylalanine, Serine, Glutamine and GABA (γ-aminobutyric acid). The composition contains the essential amino acids Phenylalanine; Glutamine; the non-essential amino acid Serine; and GABA (γ-aminobutyric acid) in concentrations effective to influence or modulate the neurotransmitter pentapeptide enkephalin. The composition may further comprise tetrahydrocannabinol (THC). | 2017-09-28 |
20170273938 | USE OF FLAVONOIDS IN MANUFACTURING COMPOSITIONS FOR WOUND HEALING - Disclosed is a method for wound healing comprising administering a subject in need thereof a therapeutically effective amount of a flavonoid compound, wherein the compound is preferably nonglycosylated flavone. Specifically, the present invention can be used for treating skin symptoms of a trauma, a burn, a scald and a chronic wound, and can be particularly used for healing a wound of a diabetes patient. | 2017-09-28 |
20170273939 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MULTI-DRUG RESISTANT INFECTIONS - A pharmaceutical composition for the treatment of multi-drug resistant infections includes an antimicrobial agent in combination the benzopyrano[3,4-b][1]benzopyran-12(6H)-one class of compound boeravinone B of Formula 1: | 2017-09-28 |
20170273940 | MANGIFERIN-6-O-BERBERINE SALT AND PREPARATION METHOD AND USE THEREOF - The present invention provides a mangiferin-6-O-berberine salt and a preparation method thereof, and further provides a use of the mangiferin-6-O-berberine salt for the treatment of diabetics and other diseases as an AMPK activator. | 2017-09-28 |
20170273941 | MAST CELL STABILIZERS TREATMENT FOR SYSTEMIC DISORDERS - Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders, are provided. | 2017-09-28 |
20170273942 | Taxane Analogs for the Treatment of Brain Cancer - Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer. | 2017-09-28 |
20170273943 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV - Substituted phenylpyrrolecarboxamide compounds such as those represented by Formula A can be used in the treatment of HIV infection and related conditions. | 2017-09-28 |
20170273944 | ACTIVE METABOLITE OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-- 1H-INDOLE DIMESYLATE MONOHYDRATE AND DIMESYLATE DIHYDRATE SALT OF ACTIVE METABOLITE - The present invention is directed to active metabolite of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate of formula (I). The present invention is also directed to dimesylate dihydrate salt of formula (II). The compounds of formula (I) and formula (II) are useful in the treatment of various disorders that are related to 5-HT | 2017-09-28 |
20170273945 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION - The present invention relates to a pharmaceutical composition for topical administration comprising a compound of formula I, 3-{4-[2-{5-chloro-1-(diphenylmethyl)-2-[2-({[2-(trifluoromethyl)benzyl]sulfonyl}amino)ethyl]-1H-indol-3-yl}ethyl]sulfonyl}phenyl}propanoic acid: | 2017-09-28 |
20170273946 | EXTENDED RELEASE PHARMACEUTICAL FORMULATIONS - The present invention relates to coated extended release pharmaceutical formulations of valsartan comprising a core comprising valsartan and at least one coating layer over the core. The present invention further relates to extended release pharmaceutical formulations comprising (a) a core comprising valsartan and at least one hydrophilic swelling polymer and (b) at least one coating layer over the core wherein the coating layer in contact with the core is applied from an organic solvent based system. | 2017-09-28 |
20170273947 | N-(5-ARYLAMIDO-2-METHYLPHENYL)-5-METHYLISOOXAZOLE-4-CARBOXAMIDE DERAVATIVE, PHARMACEUTICAL ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION THEROF AND FMS KINASE INHIBITOR COMPRISING THE SAME AS ANACTIVE INGREDIENT - The present invention relates to N-(5-arylamido-2-methylphenyl)-5-methylisoquoxazole-4-carboxamide derivative, or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising same. The compound according to the present invention exhibits an FMS kinase inhibitory activity and thus can be used as pharmaceutical composition for preventing and treating diseases associated therewith. | 2017-09-28 |
20170273948 | USE OF SIGMA RECEPTOR LIGANDS IN OSTEOARTHRITIS - The invention relates to compounds of formula (I) or formula (II) | 2017-09-28 |
20170273949 | AGENT FOR PREVENTING AND/OR TREATING OPHTHALMOLOGIC DISEASES - It is an object of the present invention to provide a novel medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis. According to the present invention, provided is a medicament for preventing and/or treating ophthalmologic diseases caused by ocular angiogenesis, which comprises, as an active ingredient, a pyrazolone derivative such as 3-methyl-1-phenyl-2-pyrazolin-5-one, or a physiologically acceptable salt thereof, or a hydrate thereof or a solvate thereof. | 2017-09-28 |
20170273950 | SYNTHESIS OF CYCLOCREATINE AND ANALOGS THEREOF - Provided herein is a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, using cynamide in the reaction. | 2017-09-28 |
20170273951 | ANESTHETIC COMPOUNDS AND RELATED METHODS OF USE - Provided herein are compounds according to formula (I): | 2017-09-28 |
20170273952 | METHODS OF TREATING LIVER DISEASE - The present disclosure relates to a method of preventing and/or treating liver disease comprising administering an ASK1 inhibitor in combination with a FXR agonist, to a patient in need thereof. | 2017-09-28 |
20170273953 | CRYSTALLINE SOLID FORMS OF 6-CARBOXY-2-(3,5-DICHLOROPHENYL)-BENZOXAZOLE - The present invention relates to solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one solid form and to the therapeutic or prophylactic use of such solid forms and compositions. | 2017-09-28 |
20170273954 | METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS - Compositions and methods are provided for treating or inhibiting a bacterial infection involving at least one antibiotic and a compound that potentiates the antibiotic activity of the antibiotic. In certain embodiments the antibiotic is a beta lactam. In further embodiments, the antibiotic is oxacillin. In additional embodiments, the potentiating compound is an inhibitor of vraSR operon expression. In specific embodiments, the bacterial infection involves an antibiotic-resistant bacteria. | 2017-09-28 |
20170273955 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY - Disclosed is a compound which is useful as an AMPK activator.
| 2017-09-28 |
20170273956 | METHODS OF INCREASING TONIC INHIBITION AND TREATING SECONDARY INSOMNIA - Methods of increasing tonic inhibition in a subject in need thereof, for example a subject with Fragile X syndrome or Angelman syndrome are disclosed. Methods of treating secondary insomnia in a subject with a neurodegenerative disease or disorder are also disclosed. The methods can include administering the subject an effective amount of 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) or a derivative thereof, or a pharmaceutically acceptable salt thereof, increase tonic inhibition in neurons of the subject; to increase slow wave sleep (SWS) and/or slow wave activity (SWA), normalize sleep architecture, reduce secondary insomnia, increase non-rapid eye movement (NREM) sleep, increase sleep continuity, enhance delta activity within NREM, increase or improve total sleep time (TST), increase or improve sleep efficiency, reduce total time awake (TAA), reduce number of awakenings (NWA), reduce latency to persistent sleep (LPS), or to reduce wake after sleep onset (WASO), in the subject, or any combination thereof. | 2017-09-28 |
20170273957 | ANTITUSSIVE COMPOSITIONS AND METHODS - Disclosed herein are compositions which include nicotinic receptor agonists, specifically of the α7 nAChR subtype, and methods for suppressing cough. | 2017-09-28 |
20170273958 | INCREASING EXPRESSION LEVEL OF APOPTOSIS-RELATED GENES BY TREATING A HUMAN SUBJECT WITH A NITROXIDE - Disclosed herein are methods for counteracting age-related decrease in gene expression or treating age-related diseases, for example cancers and autoimmune diseases, caused by decreased expression levels of a gene associated with the apoptosis pathway, using a nitroxide. Further disclosed are methods for treating a human subject in need of an increased expression level of a gene associated with the apoptosis pathway using a nitroxide. | 2017-09-28 |
20170273959 | Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene - Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing α-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for α-galactosidase A, wherein the patient has a splice site mutation in intron 4 of the nucleic acid sequence encoding α-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease. | 2017-09-28 |
20170273960 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition. | 2017-09-28 |
20170273961 | NOVEL IMINONITRILE DERIVATIVES - The invention relates to a compound of formula (I) wherein X | 2017-09-28 |
20170273962 | Inhibitors of Hepatitis C Virus Polymerase - The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R | 2017-09-28 |
20170273963 | PHARMACEUTICAL COMPOUNDS AND USE OF SAME IN CANCER AND TAUOPATHIES - Disclosed are compounds of formula (I)-(V): where the substituents are as provided herein. Further disclosed are methods of inhibiting tau aggregation, treating or ameliorating a tauopathy or cancer by administration of such a compound. Tau is a microtubule-binding protein that accumulates in a number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease (AD). The presence of abnormal tau correlates with neuron loss and memory deficits in patients with AD and other neurodegenerative disorders that involve tau accumulation. | 2017-09-28 |
20170273964 | FATTY ACID SYNTHASE INHIBITOR FOR USE IN THE TREATMENT OF DRUG RESISTANT CANCER - Compounds that are fatty acid synthesis modulators are provided. The compounds may be used in pharmaceutical compositions to treat taxane-resistant cancers. Methods are provided for treating taxane-resistant cancer in a subject. Methods are also provided for increasing the sensitivity of a cancer cell to taxanes (i.e., paclitaxel, Nab-paclitaxel docetaxel, and/or cabazitaxel) treatment. | 2017-09-28 |
20170273965 | TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 - The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula (I) are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions. | 2017-09-28 |
20170273966 | TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 - The present invention relates to a compound represented by formula I:and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardio renal diseases such as chronic kidney diseases and heart failure and related diseases and conditions. | 2017-09-28 |
20170273967 | QUINOLINE CARBOXAMIDES FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA - A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma. | 2017-09-28 |
20170273968 | MAO-B INHIBITORS AND REHABILITATION - Methods of rehabilitation of neurological disorders, including neurological deficits associated with neurotraumas, such as stroke and traumatic brain injury, and with muscle disorders, that includes administering to a subject a MAO-B inhibitor. | 2017-09-28 |
20170273969 | Antidiabetic Solid Pharmaceutical Compositions - Provided are pharmaceutical compositions in solid form comprising a selective modulator of PPAR-γ suitable for oral dosage to treat subjects having PPAR-γ mediated conditions. Provided further are methods of manufacturing the compositions, and methods of treating a PPAR-γ mediated condition. | 2017-09-28 |
20170273970 | Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders - The invention relates to certain compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders that are, at least partially, mediated by TSPO activity. | 2017-09-28 |
20170273971 | Epimorphic Regeneration and Related Hydrogel Delivery Systems - Methods and compositions are described for enhancing tissue regeneration or wound repair in a mammalian subject comprising a composition comprising (a) a proline hydroxylase inhibitor component or molecule that increases or upregulates HIF1a and (b) a carrier component comprising a hydrogel. | 2017-09-28 |
20170273972 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS - The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators. | 2017-09-28 |
20170273973 | Novel Alpha-Hydroxy Carboxylic Acid and Derivatives and Other GRAS-Based Prodrugs of Oxymorphone and Uses Thereof - The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to the opioid oxymorphone, in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal use, and overdose. When delivered at the proper dosage, the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent. | 2017-09-28 |
20170273974 | PATCH PREPARATIONS WITH MISUSE PREVENTION FEATURES - The present disclosure provides a patch preparation having features that prevent misuse. In some embodiments, a patch preparation containing a plaster on a support, wherein the plaster comprises a solvent having a vapor pressure equal to or greater than 1 kPa at 20° C. The patch preparation can lose its adhesion after the plaster is exposed to air and at least some of the solvent has evaporated, or if the patch is removed from the skin. This feature prevent the used patch from being applied to the skin again, and can prevent misuse. A method of forming a patch preparation is also disclosed. | 2017-09-28 |
20170273976 | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS - The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved. | 2017-09-28 |
20170273977 | SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE - The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders. | 2017-09-28 |
20170273978 | IMIDAZOYL ANILIDE DERIVATIVES AND METHODS OF USE - The present invention provides kinase inhibitor analogs with improved properties, such as improved efficacy, pharmacokinetics, safety, and specificity. In some embodiments, the present invention provides nilotinib analogs that provide therapeutic benefits. | 2017-09-28 |
20170273980 | BENZYL SUBSTITUTED INDAZOLES AS BUB1 INHIBITORS - Compounds of formula (I) as defined herein and their use as pharmaceuticals. | 2017-09-28 |
20170273981 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS - The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders. | 2017-09-28 |
20170273982 | PULSE DOSING REGIMEN AND METHODS OF TREATMENT - A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein. | 2017-09-28 |
20170273983 | PYRROLOPYRIMIDINE COMPOUNDS USED AS TLR7 AGONIST - The present invention relates to a pyrrolopyrimidine compound as TLR7 agonist, and particularly relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, a preparation process thereof, a pharmaceutical composition containing such compounds and use thereof for manufacturing a medicament against viral infection. | 2017-09-28 |
20170273984 | COMPOSITION COMPRISING (6S)-5-METHYL TETRAHYDROFOLIC ACID OR SALT THEREOF, AND PREPARATION AND USE THEREOF - Disclosed are a composition including (6S)-5-methyl tetrahydrofolic acid or a salt thereof, and preparation and use thereof. In the composition, the content of (6S)-5-methyl tetrahydrofolic acid or the salt thereof is not less than 98.0%, the content of a related impurity JK12A is not greater than 0.1%, and 5-methyl tetrahydropterioic acid is not detectable. | 2017-09-28 |
20170273985 | TRICYCLIC DERIVATIVE - Disclosed are compounds useful as inhibitors of phosphodiesterase 1 (PDE1), compositions thereof, and methods of using the same. | 2017-09-28 |
20170273986 | METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS - Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound. | 2017-09-28 |
20170273987 | Methods for Treating GI Syndrome and Graft versus Host Disease - We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases. | 2017-09-28 |
20170273988 | METHODS OF TREATING LYMPHOMA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS - A method of treating lymphoma in a mammal comprises the step of: administering to a patient a pharmaceutical acceptable amount of a compound being a thienotriazolodiazepine compound of the Formula (1) wherein R | 2017-09-28 |
20170273990 | METHODS FOR THE SEPARATION AND DETECTION OF AN OXYSTEROL - Assay methods for determining purity of a sample of a sterol are provided. These methods include providing an HPLC eluent including a sterol, other compounds related to the sterol and a mobile volatile phase; generating an aerosol of liquid droplets from the HPLC eluent; drying the liquid droplets to obtain residue particles of the sterol; contacting the residue particles of the sterol with an ion stream which applies a size-dependent electrical charge to each of the residue particles to generate an electrical signal and measuring the electrical signal to determine the purity of the sterol in the sample. The sterol can be OXY133 or OXY133 monohydrate. | 2017-09-28 |
20170273991 | TREATMENT OF CONGESTION USING STEROIDS AND ADRENERGICS - A decongestant composition is provided comprising: (a) a safe and effective amount of an adrenergic compound; (b) a safe and effective amount of a steroid; and (c) a pharmaceutically-acceptable carrier. Methods of treating congestion in a human or animal subject are also provided comprising administering to the subject a composition comprising: (a) an adrenergic compound; and (b) a steroid; where the daily dose of the adrenergic compound administered to the subject is from about 1 μg to about 800 μg, and the daily dose of the steroid administered to the subject is from about 1 μg to about 400 μg. | 2017-09-28 |
20170273992 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING GLUCOCORTICOID-INDUCED CORNEAL OR SKIN THINNING - The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof. | 2017-09-28 |
20170273993 | PHARMACEUTICAL COMPOSITION CONTAINING GINKGOLIDE B AND BLOOD PLATELET PROSTAGLANDIN CYCLOOXYGENASE INHIBITOR AND METHOD FOR PREPARATION THEREOF AND USE THEREOF - Provided is a pharmaceutical composition containing ginkgolide B and the blood platelet prostaglandin cyclooxygenase inhibitor aspirin, a method for preparation of the pharmaceutical composition and a use thereof. When used together, ginkgolide B and aspirin have a synergistic effect in resisting platelet aggregation. | 2017-09-28 |
20170273994 | Compositions and Methods for Combination Antiviral Therapy - The present invention relates to therapeutic combinations of [2-(6-amino-purin-9 yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2 hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations. | 2017-09-28 |
20170273995 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF - A method for treating cancer is disclosed. The method comprises administering to a subject in need thereof, an effective amount of a pharmaceutical composition comprising monoethanolamine, its prodrug or hybrid molecule or a pharmaceutically acceptable salt thereof, and a pharmaceutically effective carrier. Also disclosed is a composition comprising monoethanolamine or a pharmaceutically acceptable salt thereof and a pharmaceutically effective carrier, wherein the pharmaceutical composition is formulated for oral, intravenous, intraperitoneal, subcutaneous, dermal, or intranasal administration. | 2017-09-28 |
20170273996 | Dosing Regimens for Treating And/Or Preventing Cerebral Amyloidoses - Described herein are dosing regimens and kits for the treatment and/or prevention of cerebral amyloidoses such as Alzheimer's disease (AD) and/or cerebral amyloid angiopathy (CAA). | 2017-09-28 |
20170273997 | PREBIOTICS FOR REDUCING THE RISK OF OBESITY LATER IN LIFE - The invention proposes a nutritional composition comprising selected oligosaccharides that reduces the abundance of | 2017-09-28 |
20170273998 | COMPOSITIONS BASED ON SAFFRON FOR THE PREVENTION AND/OR TREATMENT OF CORNEAL DYSTROPHIES - The present invention relates to a pharmaceutical, dietary and/or food composition, comprising saffron for use in the prevention and/or treatment of corneal dystrophies. The present invention also relates to a combination comprising saffron and at least one antioxidant and to a pharmaceutical dietary and/or food composition comprising said combination for use in the prevention and/or treatment of corneal dystrophies. | 2017-09-28 |
20170273999 | METHOD FOR PRODUCING SOLID DISPERSION CONTAINING HARDLY SOLUBLE POLYPHENOL - Provided is a method of producing a solid dispersion that can improve solubility of a hardly soluble polyphenol in water. Specifically, provided is a method of producing a solid dispersion containing an amorphous hardly soluble polyphenol, the method including the steps of: mixing (A) a hardly soluble polyphenol, (B) at least one selected from the group consisting of a plant-derived polysaccharide, a seaweed-derived polysaccharide, and a microorganism-derived polysaccharide, a plant-derived polypeptide, and a microorganism-derived polypeptide, and (C) at least one selected from the group consisting of a monosaccharide and a disaccharide, followed by melting of the mixture by heating; and solidifying the molten product by cooling. | 2017-09-28 |
20170274000 | TRIGGERING RNA INTERFERENCE WITH RNA-DNA AND DNA-RNA NANOPARTICLES - The instant invention provides RNA nanocubes, DNA nanocubes and R/DNA chimeric nanocubes comprising one or more functionalities. The multifunctional RNA nanocubes are suitable for therapeutic or diagnostic use in a number of diseases or disorders. | 2017-09-28 |
20170274001 | Compositions and Methods for Increasing Red Blood Cells - The invention relates generally to a composition and method for increasing the frequency, amount, or presence of red blood cells in peripheral blood. In one embodiment, the invention comprises the inhibition of, or genetic modification of the genes encoding, one or more scavenger receptors. In one aspect, the invention relates to treatments of anemia. | 2017-09-28 |
20170274002 | MULTIPLE FOLATE FORMULATION AND USE THEREOF - A multiple folate composition comprising the following three different forms of folate: a folic acid (a salt or ester thereof); a folinic acid (a salt or ester thereof); and a 5-methyl-tetrahydrofolicacid (a salt or ester thereof) and other non-folate ingredients. The composition is useful as a nutritional supplement or medication in the treatment of a folate deficiency and sequella thereof and/or in conditions responsive to administration of a metabolically useful folate. The compositions are particularly of use in patients who have impaired or reduced ability to convert folic acid to its metabolically active forms and in the treatment of depression, particularly in pregnant women or women who may become pregnant. | 2017-09-28 |
20170274003 | BLOCKING PIRB UPREGULATES SPINES AND FUNCTIONAL SYNAPSES TO UNLOCK VISUAL CORTICAL PLASTICITY AND FACILITATE RECOVERY FROM AMBLYOPIA - Targeting and disrupting paired-immunoglobulin-like receptor B (PirB) function increases synaptic connectivity and plasticity even after the critical period, and can enable significant structural and functional recovery from amblyopia. Provided are compositions comprising PirB, or LILRB2 (leukocyte immunoglobulin-like receptor 2) polypeptides for disrupting PirB/LILRB2 signaling, and methods of using the compositions for treating disorders associated with reduced synaptic plasticity including amblyopia. | 2017-09-28 |
20170274004 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS - The invention provides methods of inducing an immune response to cancer comprising co-administering to a cancer patient one or more TLR9 agonists and one or more checkpoint inhibitors. Preferably, the one or more TLR9 agonists are administered to the patient via intratumoral (i.t.) administration. | 2017-09-28 |
20170274005 | TREATMENT OF RETINITIS PIGMENTOSA USING HYALURONIC ACID-CARBON NANOMATERIAL-PHOTOSENSITIZER COMPLEX - Disclosed is a complex for remedying or treating a retinal disease. The complex includes a hyaluronic acid or a derivative thereof, a carbon nanomaterial covalently bonded to the hyaluronic acid or the derivative thereof, and a photosensitizer bonded to the carbon nanomaterial. The complex for remedying or treating the retinal disease according to the present invention includes a hyaluronic acid-carbon nanomaterial-photosensitizer complex, thus selectively preventing the formation of active oxygen in retinal pigment epithelium cells for a relatively long period of time. Accordingly, the complex has excellent therapeutic efficacy and easily infiltrates into cells. Further, the present invention provides a composition for remedying or treating a retinal disease including the hyaluronic acid-carbon nanomaterial-photosensitizer complex. | 2017-09-28 |
20170274006 | NASAL COMPOSITION COMPRISING MIXTURE OF HYALURONIC ACIDS AND SALINE SOLUTION - The invention relates to a nasal composition comprising a saline base, an active agent and a mixture of a first hyaluronic acid having a molecular weight of at most 10 | 2017-09-28 |
20170274007 | PREBIOTIC INULIN BASED PREPARATION - The present invention relates to an inulin-based prebiotic complex enriched with vitamin B12 and selenium, which finds use in the field of food, nutraceutical, herbal, pharmaceutical preparations. | 2017-09-28 |
20170274008 | Use of polysaccharide in Dendrobium officinale for anti-fatigue - The present invention relates to a glucomannan with a molecular size of 730 kDa, called DOP, which was previously identified as the unique authentication marker of the expensive herb | 2017-09-28 |
20170274009 | COMPOSITIONS AND METHODS TO AFFECT SKIN IRRITATION - Compositions are described that contain treated chitosan, modified chitosan and/or modified and treated chitosan for use in formulations for skin, hair and nails, and in compositions and methods of reducing topical agent-induced skin irritation and inflammation. | 2017-09-28 |
20170274010 | IMMUNE MODULATION USING PEPTIDES AND OTHER COMPOSITIONS - The present invention generally relates to compositions and methods for topical or transdermal delivery for immune modulation. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2017-09-28 |
20170274011 | INJECTABLE SLURRIES AND METHODS OF MANUFACTURING AND USING THE SAME - One aspect of the invention provides a slurry comprising: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a biocompatible surfactant. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; a biocompatible surfactant; and a foam comprising a plurality of gas bubbles. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a biocompatible excipient. Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a lipolytic agent. | 2017-09-28 |
20170274012 | Acceleration of Reconstitution of Plasma Powder by Mixing with Small Beads - Methods of accelerating the reconstitution of plasma powder by mixing the powder with small beads is disclosed. The beads can be, for example, glass and/or plastic resin beads having a diameter from about 2 mm to about 6 mm. The plasma powder can be, for example, a spray-dried plasma powder. A method is provided of accelerating the reconstitution of a dry protein powder in a fluid that includes, but is not limited to, the steps of providing both a dry protein powder and small beads in a container, adding a reconstitution fluid to the container, and manipulating the dry protein powder and the small beads to dissolve the dry protein powder in the reconstitution fluid. | 2017-09-28 |
20170274013 | WOUND FLUID ELEVATED PROTEASE ENZYME INHIBITION THROUGH CAMELID BLOOD PRODUCTS - Camelid blood products their peptide isolates and synthetic sequences for wound fluid elevated protease enzyme inhibition. The present invention provides evidence that Metalloprotease and other Protease enzyme (e.g. elastase) peptide inhibitors are present in camelid serum/plasma can be used alone or combined with other agents to enhance healing in the treatment of chronic wounds and burns by inhibiting elevated wound fluid protease activity. These protease enzymes inhibitors present in camelid serum/plasma can be demonstrated to inhibit chronic non-healing wound fluid proteolytic enzymes by the use of wound fluid assay kits specifically designed to measure wound fluid protease activity. The serum/plasma and isolated or synthesised peptides of this patent have use in the treatment of a range of cosmetic skin indications and diseases such as disorders of the gastrointestinal tract, cardiovascular conditions and specifically in the treatment of wound healing and burns and in scar tissue healing. | 2017-09-28 |
20170274014 | COMBINATIONS OF LOW, IMMUNE ENHANCING, DOSES OF MTOR INHIBITORS AND CARS - The invention relates, in part, to a method of treating a subject comprising administering to the subject a low, immune enhancing of a mTOR inhibitor and an immune effector cell engineered to express a CAR. | 2017-09-28 |
20170274015 | PLATELET RICH PLASMA FORMULATIONS AND USE THEREOF - Compositions for platelet rich plasma (PRP) are provided. Generally, these compositions comprise a higher concentration of platelets than whole blood. Concentrations of lymphocytes, monocytes, and neutrophils may be different from concentrations found in whole blood. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue, particularly spinal disc, and/or to slow or stop cardiac apoptosis after a heart attack. | 2017-09-28 |
20170274016 | METHODS FOR INCREASING OSTEOBLASTIC FUNCTION - The present disclosure provides methods of increasing osteoblastic function in a subject, the method comprising systemically administering to the subject a population of stem cells and/or progeny thereof and/or soluble factors derived therefrom. | 2017-09-28 |
20170274017 | BONE FRACTURE HEALING WITH PRIMED DISTAL BONE MARROW MESENCHYMAL STROMAL CELLS - Methods, systems and activated human mesenchymal stromal cells (hMSCs) from bone marrow regions distal from bone fractures, the hMSCs enhanced for encouraging healing of bone fractures. Systems and methods of activation for enhancing bone fracture healing hMSCs, and the enhanced cells themselves, by exposing and activating distally obtained bone marrow aspirate to acoustic energy prior to placement of the activated cells at a site of a bone fracture. | 2017-09-28 |
20170274018 | ARTIFICIAL CARTILAGE CONTAINING CHONDROCYTES OBTAINED FROM COSTAL CARTILAGE AND PREPARATION PROCESS THEREOF - The present invention relates to an artificial cartilage containing mesenchymal stem cell (MSC)-like dedifferentiated cells obtained by passage culturing costal chondrocytes, and a preparation process thereof. | 2017-09-28 |
20170274019 | RETINAL GANGLION CELLS AND PROGENITORS THEREOF - Methods are provided for the production of retinal ganglion (RG) progenitor cells and mature RG cells from pluripotent stem cells optionally under feeder-free conditions, and further optionally under xeno-free conditions. Additionally provided are compositions of RG progenitor cells and mature RG cells, as well as methods of use thereof including therapeutic use thereof. Exemplary methods may produce substantially pure populations and cultures of RG progenitor cells and mature RG cells. | 2017-09-28 |
20170274020 | OSTEOINDUCTIVE PUTTIES AND METHODS OF MAKING AND USING SUCH PUTTIES - The present disclosure relates to osteoinductive putties and other implantable compositions for repair of bone defects and other medical uses. Specifically, the technology pertains to carriers for use in implantable compositions, such as osteoinductive putties. The osteoinductive putties are made entirely from donor tissue such as demineralized bone matrix, and the putties have excellent physical properties. The present disclosure relates to osteoinductive putties, carriers, compositions, implants, kits, methods of making and methods of using any of the foregoing. | 2017-09-28 |
20170274021 | Method for preparing a biological tissue construct and use of autologous cells obtained specifically - The method for preparing a tissue construct for medical purposes uses endothelial progenitor cells (EPC) which have not been passaged multiple times and have a content of EOEC (early outgrowth endothelial progenitor cells) and LOEC (late outgrowth endothelial progenitor cells). These cells and fibroblasts and/or muscle cells, viz. myoblasts, myofibroblasts, smooth muscle cells or the progenitors thereof, are, in the form of living cells, seeded onto a matrix or introduced into a matrix in order to yield the tissue construct following further treatment steps. The matrix is preferably a protein preparation, more particularly a fibrinogen preparation. Both the cells and the fibrinogen preparation can be obtained from a single blood sample from a patient. Apart from the preparation of bypass materials, prosthetic vascular graft, tissue patches, conduits and the like, the EOEC-containing EPC culture or suspension is suitable as means for cell transplantation. | 2017-09-28 |
20170274022 | MICROBIOTA RESTORATION THERAPY (MRT), COMPOSITIONS AND METHODS OF MANUFACTURE - Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag. | 2017-09-28 |
20170274023 | PROCESS FOR ENHANCING THE VIABLE COUNTS OF LACTIC ACID BACTERIA AND USEFUL COMPOSITIONS THEREOF - Disclosed herein is (i) a method related to the growth promotional activity of plant based fibres on | 2017-09-28 |
20170274024 | AAV Vectors Targeted to Oligodendrocytes - The invention relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes. | 2017-09-28 |
20170274025 | ONCOLYTIC HSV VECTOR - The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention. | 2017-09-28 |
20170274026 | METHOD OF MAKING TRITERPENOIDS FROM PETRI DISH CULTUREDANTRODIA CINNAMOMEA - A method of making triterpenoids from petri dish cultured Antrodia cinnamomea includes: A. providing petri dish cultured Antrodia cinnamomea in an extracting container; B. providing a supercritical solvent to the extracting container to obtain an Antrodia cinnamomea extract; sending the Antrodia cinnamomea extract to a chromatographic column to separate impurities and triterpenoids from the Antrodia cinnamomea extract, and removing the impurities, and collecting the triterpenoids containing fraction; and C. testing the bioactivity of the triterpenoids containing fraction by cytotoxicity test, cell morphology analysis, cell cycle and apoptosis test, and cell motility test to find an anti-cancer effect of the triterpenoids. | 2017-09-28 |
20170274027 | Cannabis-Hemp Animal Feed - The present invention provides a commercial process for preparing the ‘Cannabis-Hemp Animal Feed’ into a feed grade nutritional supplement. The process produces both a fully cooked, and raw feed product combined, that can be inserted into an edible consumption vessel of any type, or processed into any shape, for animal ingestion purposes. | 2017-09-28 |
20170274028 | METHOD OF JUICING CANNABIS PLANT MATTER - A method is provided, comprising steps: (a) harvesting | 2017-09-28 |
20170274029 | USES OF MESEMBRYANTHEMUM CRYSTALLINUM L. CALLUS EXTRACT IN DELAYING SKIN CELL AGING, NURSING SKIN, TREATING AND PREVENTING SKIN CANCER | 2017-09-28 |
20170274030 | BUCCAL AND SUBLINGUAL CANNABINOID FORMULATIONS AND METHOD OF MAKING THE SAME - A cannabinoid troche including polyethylene glycol (or other base ingredients such as gelatin and/or pectin) and oils of peppermint, ginger, citrus, mango, etc., that is administered buccally and/or sublingually. This dosage form demonstrates an improved efficacy with reduced side effects when compared to formulations of cannabinoids in capsules, oral solutions, tinctures, sprays and edibles. The troches avoid harmful preservatives (e.g., BHT, BHA), heavy metals and stabilizers while addressing sub-therapeutic dosing and optimizing the synergistic qualities of the ratios of the individual cannabinoids, terpenes and flavonoids. The use of peppermint oil (and others) in the troche shows improved efficacy above and beyond that which is expected or seen without its use. The troches further allow for accurate and reproducible therapeutic effects with ease of dosage adjustments. | 2017-09-28 |
20170274031 | Composition for and Method of Treating Neurological Conditions - A method of treating neurological condition in a subject by administration of a pharmaceutical composition that excludes cardiac glycoside and excludes polysaccharide obtained from | 2017-09-28 |
20170274032 | PHARMACEUTICAL COMPOSITIONS FOR TREATING ANXIETY - Pharmaceutical compositions or functional foods for treating anxiety comprising ginseng saponin (Rg1+Rb1), glycyrrhizic acid and jujuba cAMP. Experiments demonstrate that as compared with the preferred drug for treating diazepam in the art, the present invention has significant anxielytic efficacy. | 2017-09-28 |
20170274033 | Methods and Materials for Increasing Lean Muscle Mass - A composition containing cinnamon extract is provided to increase lean muscle mass in a subject. Also described is a method of increasing lean muscle mass in a subject through the administration of the cinnamon extract. In some aspects, a daily dose of 10-1,000 mg of the cinnamon extract supplement is administered to the subject for a period of 6 weeks to 6 months. | 2017-09-28 |
20170274034 | A METHOD AND COMPOSITION FOR TREATING BREAST CANCER - The invention disclosed herein relates to the use of an extract of | 2017-09-28 |
20170274035 | COMPOSITIONS COMPRISING EXTRACTS OR MATERIALS DERIVED FROM PALM OIL VEGETATION LIQUOR FOR INHIBITION OF VISION LOSS DUE TO ANGIOGENESIS AND METHOD OF PREPARATION THERE - The present invention relates generally to a composition comprising palm fruit juice for use in a method of preventing and inhibiting vision loss due to angiogenesis related diseases. The composition of the present invention aids to decrease in CNV size using confocal microscopy, in addition to reduction in macrophage infiltration using immune staining; decrease in VEGF-A-induced angiogenesis using established cornea pocket assay, inhibition of IKB-D phosphorylation in laser treated choroidal tissues and reduction in macrophage recruitment to CNV lesions. | 2017-09-28 |
20170274036 | SYSTEMS, DEVICES, AND METHODS FOR SUBCUTANEOUS THERAPEUTIC TREATMENT - An implantable medical device includes a body that has a flexible outer layer encapsulating a composition. The composition includes one or more first microspheres, one or more second microspheres, and a carrier. Each first microsphere includes a first therapeutic agent and a wall containing a first biodegradable polymer that encapsulates the first therapeutic agent. Each second microsphere includes a second therapeutic agent and a wall containing a biodegradable polymer that encapsulates the second therapeutic agent. | 2017-09-28 |